The antibody drug developer, majority owned by Luye Pharma, pushed its valuation past $850m in a round backed by Bank of China’s BOCG vehicle.
Month: January 2021
Terns earns $87m in series C round
Eli Lilly invested directly and through its Lilly Asia Ventures fund, in a round that brought liver disease-focused drug developer Terns’ overall funding to $197m.
AMP Robotics accesses $55m in series B
GV and Sidewalk Infrastructure Partners contributed to a $55m round that will support the recycling robot maker’s expansion plans.
RapidSOS wraps up new funding
Microsoft, CSAA, Motorola Solutions and AAA-backed emergency response technology developer RapidSOS has secured $51.2m in new funding.
Oxbotica boxes up $47m
The autonomous driving software provider completed a series B round led by BP Ventures that also featured corporate investors Tencent and Halma.
Bibit bolstered by EV Growth-backed round
EV Growth took part in a $30m round for the robo-adviser developer, which had been acquired by Stockbit in early 2019.
Barbeque Nation serves equity stake to Jubilant
Jubilant Foodworks is providing $12.9m for the barbeque restaurant operator at a valuation of about $115m.
Abundant innovation capital
This is the second part of the speech we are preparing for the publication of the World of Corporate Venturing annual review and our next GCVDigitalForum.com on January 21 to 27. Yesterday we published the synopsis, while today’s leader will look in more detail at the abundant innovation capital, Wednesday’s will show how markets are blurring and Thursday’s will show the added value now required. Our next podcast episode will pick up the feedback – your insights will be much appreciated. Email jmawson@mawsonia.com by Friday 2pm UK time.
Powerlist Q&A – Derek Idemoto, Cisco Investments
Q&A with Derek Idemoto, SVP of corporate development and Cisco Investments
Tencent sparks $279m Enflame series C round
Tencent made its fourth investment in data centre technology provider Enflame Technologies, which has now raised more than $470m altogether.
Aeva picks up $200m Sylebra Capital investment
Porsche and Lockheed Martin-backed lidar sensor technology developer Aeva will get the funding once its reverse merger with InterPrivate Acquisition Corp closes.
Angelini Pharma carves out $960m Arvelle purchase
SK Biopharmaceuticals will divest a 12% stake in Arvelle, which is looking to commercialise an epilepsy drug treatment, through the acquisition.
Ikena Oncology strikes up $120m round
Bristol Myers Squibb participated in a series B round for the oncology drug developer that pushed its overall funding to $168m.
IconOVir Bio conducts $77m series A
The oncolytic virus therapy-based cancer drug developer raised $77m in a GV-backed series A round as it prepares to file an IND application next year.